On 28 January 2026, nChroma Bio dosed the first participant in its Phase 1/2 clinical trial of CRMA-1001, an investigational CRISPR-Cas-based...
nChroma Bio has received regulatory clearance in Hong Kong to initiate a Phase 1/2 clinical trial of its lead candidate CRMA-1001, marking the first...
Some of the best links we picked up around the internet
